Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Posts Quarterly Earnings Results, Beats Expectations By $0.32 EPS

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) issued its earnings results on Thursday. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.32, FiscalAI reports. Armata Pharmaceuticals had a negative net margin of 3,467.04% and a negative return on equity of 12.24%. The firm had revenue of $3.17 million during the quarter, compared to analysts’ expectations of $0.45 million.

Armata Pharmaceuticals Price Performance

ARMP stock remained flat at $3.72 during midday trading on Friday. 5,991 shares of the company’s stock traded hands, compared to its average volume of 118,808. The firm has a 50-day moving average of $3.83 and a 200-day moving average of $6.86. The company has a market cap of $138.31 million, a price-to-earnings ratio of -0.49 and a beta of 1.54. Armata Pharmaceuticals has a 52 week low of $2.74 and a 52 week high of $14.98.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of Armata Pharmaceuticals in a research report on Tuesday, September 22nd. Two equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $15.00.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals is a clinical-stage biotechnology company developing bacteriophage-based treatments for bacterial infections. Bacteriophages are viruses that infect and kill specific bacteria, and Armata’s approach is intended to target disease-causing bacteria, including strains that are difficult to treat with antibiotics. The company’s development programs have included AP-PA02, an inhaled phage therapy being studied for Pseudomonas aeruginosa lung infections, and AP-SA02, an intravenous therapy targeting Staphylococcus aureus infections.